Sort   by:  
 Page size 
UnknownFibroblast growth factor 21 mediates specific glucagon actions.
Not available
S-EPMC3636653 | biostudies-literature
UnknownCommonalities and differences in injured patient experiences of accessing and receiving quality injury care: a qualitative study in three sub-Saharan African countries.
Not available
S-EPMC11218010 | biostudies-literature
UnknownDexamethasone for adult patients with a symptomatic chronic subdural haematoma (Dex-CSDH) trial: study protocol for a randomised controlled trial.
Not available
S-EPMC6280536 | biostudies-literature
UnknownImpact of liver cirrhosis, the severity of cirrhosis, and portal hypertension on the outcomes of minimally invasive left lateral sectionectomies for primary liver malignancies.
Not available
S-EPMC10986843 | biostudies-literature
UnknownTime-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Not available
S-EPMC12214479 | biostudies-literature
UnknownA Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Not available
S-EPMC8518716 | biostudies-literature
UnknownExploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Not available
S-EPMC12170883 | biostudies-literature
UnknownUnderstanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial.
Not available
S-EPMC7657351 | biostudies-literature
UnknownMapping the human genetic architecture of COVID-19.
Not available
S-EPMC8674144 | biostudies-literature
UnknownAge-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.
Not available
S-EPMC8631592 | biostudies-literature
Sort   by:  
 Page size